Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort. CASE PRESENTATION: Here we report an idiosyncratic reaction to sorafenib resulting in fatal hepatotoxicity and associated renal failure in a 62 year-old man treated with sorafenib within the SORCE trial. CONCLUSION: This is the first reported case of sorafenib exposure associated fatal toxicity in the adjuvant setting and highlights the unpredictable adverse effects of novel adjuvant therapies.

Original publication

DOI

10.1186/1471-2407-12-590

Type

Journal article

Journal

BMC Cancer

Publication Date

11/12/2012

Volume

12

Keywords

Acute Kidney Injury, Antineoplastic Agents, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Fatal Outcome, Humans, Kidney Neoplasms, Male, Middle Aged, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Sorafenib